Clinical Research | Carolina Eye Associates Southern Pines, NC
Blue Pre-Loader Bar

Clinical Research

Updated 7.5.22

Carolina Eye Associates participates in national and international clinical research studies, often referred to as clinical trials, which allows for the scientific testing necessary to develop new and improved drugs and therapies. These studies are tightly regulated and most are controlled by the USDA.

In a clinical trial, new drugs and therapies are tested in a scientific way. In some trials, half of the patients receive an experimental therapy and the other half receive a placebo (a harmless pill or medicine that has no therapeutic effect). During this type of trial, neither the patient nor the doctor knows which therapy the patient has received. This is done to eliminate bias and subjectivity in the results.

Because most clinical trials require very specific clinical findings to be present in study patients, some patients are not eligible to participate in the trials. For more information about these trials, please contact our clinical trial coordinator, Lisa Fulghum at Lisa can provide additional information about the inclusion and exclusion criteria for each study.

Carolina Eye is currently participating in the following clinical trials:

Verana Health, Inc./”Field Test of Glaucoma Outcomes Survey” (GOS) – Currently recruiting/enrolling
Purpose: To determine how useful a questionnaire, the GOS, is as a tool for measuring patient quality of life after undergoing minimally invasive glaucoma surgery combined with cataract surgery.

Genentech, Inc./ML43435 – Elevatum
A Phase 4, multicenter, open-label, single-arm study to investigate Faricimab (RO6867461) treatment response in treatment-naïve, underrepresented patients with Diabetic Macular Edema (DME).
Purpose: To explore relationships over time between different kinds of assessments (vision, imaging, eye chemistry, and genetics) in participants with DME who are treated with Faricimab. This study will also evaluate the effects, good or bad, that Faricimab has on patients with DME who are treated with Faricimab.

Genentech, Inc./GR43341 – Villa
A prospective, observational, post marketing surveillance study to monitor the safety of the port delivery system with Ranibizumab in patients with Neovascular Age-Related Macular Degeneration.
Purpose: To gain insights about how well the Port Delivery System with ranibizumab is tolerated by patients to whom it is prescribed in routine medical practice, particularly if a large number of patients participate; for example, little known side effects of the treatment may be detected. This information will help doctors to know better how to use the Port Delivery System with ranibizumab and may optimize the treatment of patients.